An open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression

Trial Profile

An open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Dolutegravir (Primary) ; Lamivudine (Primary) ; Abacavir; Abacavir/dolutegravir/lamivudine; Atazanavir; Darunavir; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Emtricitabine; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir disoproxil fumarate; Etravirine; Lamivudine/abacavir; Lopinavir/ritonavir; Nevirapine; Raltegravir; Rilpivirine; Ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms DOLAM
  • Most Recent Events

    • 28 Mar 2018 Results (n=91) of ongoing Phase A at 24 weeks published in the Journal of Antimicrobial Chemotherapy
    • 01 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top